D endritic cells (DC)3 are highly specialized APCs that take up exogenous material from the extracellular environment for presentation in the context of MHC molecules. Next to presentation of antigenic epitopes on MHC class II molecules to CD4 ϩ T cells, DCs can also shuttle Ag to the MHC class I processing pathway for CD8 ϩ T cell activation, a process termed crosspresentation (reviewed in Ref. 1). This enables DCs that have engulfed tumor Ag to activate Ag-specific CD8 ϩ T cells capable of tumor cell killing. The cytotoxic antitumor effect of CD8 ϩ T cells also depends on CD4 ϩ T cells, which provide CD8 ϩ T cells with growth factors and costimulatory signals (2-5). Thus, cancer vaccines should aim at inducing both antitumor CD4 ϩ and CD8 ϩ T cell responses.Tumor vaccines based on full-length recombinant proteins have the potential to generate broad-based CD4 ϩ and CD8 ϩ T cell responses (6). However, using recombinant tumor Ag, we found that cross-presentation of soluble Ag by DCs is highly inefficient, whereas presentation to CD4 ϩ T cells was readily induced (7). Delivering tumor Ag to the MHC class I processing machinery in DCs is thus a challenge in the design of cancer vaccines and requires a better understanding of the mechanisms of cross-presentation.Ag processing via MHC class I and II pathways largely depends on the route of Ag uptake. Receptors facilitating cross-presentation include members of the C-type lectin receptor family, FcR, and integrins (reviewed in Ref. 8). Because most CD8 ϩ T cell epitopes are generated in the cytosol, where cleavage of the Ag by the proteasome and other protease complexes occurs (9), Ag translocation from endocytic compartments into the cytosol is essential for effective cross-presentation. Peptides generated by cytosolic proteases are then transported via TAP into the endoplasmic reticulum where additional trimming may occur (10) to allow loading of optimal length peptides onto nascent MHC class I molecules and subsequent transport of the peptide MHC complexes to the cell surface for presentation to CD8 ϩ T cells. Our group has previously shown that cross-presentation of recombinant NY-ESO-1, a 180-aa protein, which is expressed in a variety of human cancers including melanoma, breast, lung, prostate, and others (11,12), by DCs depends on Ag formulation. Using NY-ESO-1 as a model Ag we found that cross-presentation efficiency was enhanced by targeting the Ag to FcR with ICs (7, 13) or by formulation of the Ag with ISCOMATRIX adjuvant, which is being developed for use in human vaccines (7). ISCOMATRIX adjuvant is based on the immune-stimulating complexes (ISCOM) technology, which combines an efficient Ag delivery system with the immunostimulatory activity of saponin and has been shown to promote humoral and cellular immune responses in a variety of animal models (reviewed in Ref. 14). HLA-A2-restricted cross-presentation of NY-ESO-1/immune complex (IC) was proteasome dependent, and for NY-ESO-1/ISCOMATRIX